Efecto de la atorvastatina sobre la progresión y regresión de los depósitos grasos renales en un modelo experimental

  1. Gracia Adánez 1
  2. M. Teresa Castells 2
  3. Bartolomé García Pérez 1
  4. M. Teresa Sánchez-Polo 1
  5. Antonia Martín Castillo 3
  6. Ignacio Ayala 4
  1. 1 Servicio de Cirugía General. Hospital Virgen de la Arrixaca. Murcia
  2. 2 Departamento de Biología Celular. Universidad de Murcia
  3. 3 ervicio Digestivo. Hospital Santa María del Rosell. Cartagena. Murcia
  4. 4 Departamento de Medicina y Cirugía Animal. Universidad de Murcia
Show affiliations +
Journal:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168,  1578-1879

Year of publication: 2007

Volume: 19

Issue: 5

Pages: 223-231

Type: Article

DOI: 10.1016/S0214-9168(07)74203-1 SCOPUS: 2-s2.0-35848956997 DIALNET GOOGLE SCHOLAR

More publications in: Clínica e investigación en arteriosclerosis

Abstract

Introduction There is evidence of a relationship between atherosclerosis and progressive kidney disease. However, information on the role of statins on kidney disease in humans and animal models is lacking. Objectives To analyze the effect of atorvastatin on progression/regression of renal lipid accumulation in an experimental model using histological analysis. Material and method We used 100 White-Leghorn chickens fed with a hyperlipemic diet (induction stage), followed by an interventional stage, in which the animals were fed a normal or hyperlipemic diet and administered atorvastatin or placebo. Assessment of renal lipid accumulation was made by histologic and imaging analyses. Results In the healthy control group, no intracellular renal fat deposits or accumulations were found. The atherogenic group showed substantial lipid accumulations. The intervention group with suspension of the hyperlipemic diet and atorvastatin administration showed significant differences with the remaining groups, presenting the lowest fat accumulation. This group also showed significantly lower fat accumulation diameter with respect to the remaining groups. Conclusions Our experimental model was useful and suitable for the study of renal fat accumulation. Hyperlipemic diet suspension and simultaneous atorvastatin therapy led to the lowest renal fat accumulation. Hyperlipemic diet suspension alone produced less pronounced results. The parameters studied indicate that atorvastatin was effective in accelerating regression of renal fat accumulation and in decreasing its progression.

Bibliographic References

  • Scoble JE. Atherosclerotic nephropathy. Kidney Int. 1999;71:S106-9.
  • Grone EF, Walli AK, Grone HJ, Miller B, Seidel D. The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis. 1994;107:1-13.
  • Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis: a model analogous to atherosclerosis. Am J Nephrol. 1988;8:261-71.
  • Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352:1685-95.
  • Muntner PM, Coresh J, Klag MJ, Smith JC, Eckfeldt J. Lipids and incipient hypercreatinemia: a prospective association. J Am Soc Nephrol. 1998;9:617.
  • Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoproteins abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12:1908-15.
  • Kasiske BL, O'Donnell MD, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1998;33:667-72.
  • Kees-Folts D, Diamond JR. Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. Am J Nephrol. 1993;13:365-75.
  • Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000;11:669-83.
  • Dominguez JH, Tang N, Xu W, Evan AP, Siakotos AN, Agarwal R, et al. Studies of renal injury. III. Lipid-induced nephropathy in type II diabetes. Kidney Int. 2000;57:92-104.
  • García Pérez B, Ayala I, Castells MT, Madrid JF, Ortega MR, Ortega JV, et al. Planimetric and histological study of the aorta in atherosclerotic chickens treated with nifedipine, verapamil and diltiazem. Histol Histopathol. 2003;18:1027-33.
  • García Pérez B, Ayala I, Doménech G, Sánchez Polo MT, García Partida P, Valdés M. Effects of nifedipine, Verapamil and Diltiazem on serum Biochemical parameters and aortic composition of atherosclerotic chickens. Biomed Pharmacother. 2005;59:1-7.
  • Ayala I, García Pérez B, Domenech G, Castells MT, Valdés M. Use of the chicken as an experimental model in atherosclerosis. Avian Poult Biol Rev. 2005;16:151-9.
  • Hernández-Espinosa D, Ayala I, Castells MT, García- Pérez B, Martín-Castillo A, Miñano A, et al. Intracellular retention of hepatic serpins caused by severe hyperlipidemia. Liver Int. 2006;26:708-15.
  • Keane WF, Kasiske B, O'Donnell MP, Kim Y. Hypertension, hyperlipidemia and renal damage. Am J Kidney Dis. 1993;21:43-50.
  • Huang WM, Gibson SJ, Facer P, Gu J, Polak JM. Improved section adhesion for immunocytochemistry using high molecular weight polymers of L-lysine as a slide coating. Histochem. 1983;77: 275-7.
  • Martoja R, Martoja M. Técnicas de histología animal. Barcelona: Toray-Masson; 1970.
  • Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993;87:III45-53.
  • Studer RK, Negrete H, Craven PA, DeRubertis FR. Protein kinase C signals thromboxane-induced increases in fibronectin synthesis and TGF-β bioactivity in mesangial cells. Kidney Int. 1995;48:422-30.
  • Vázquez Pérez S, Aragoncillo P, De las Heras N, Navarro-Cid J, Cediel E, Sanz R, et al. Atorvastatin prevents glomeruloesclerosis and renal endotelial dysfunction in hypercholesterolemic rabbits. Nephrol Dial Transpl. 2001;16:40-4.
  • Wilson SH, Chade AR, Feldstein A, Sawamura T, Napoli C, Lerman A, et al. Lipid lowering-independent effects of sinvastatin on the kidney in experimental hipercholesterolaemia. Nephrol Dial Transplant. 2003;18:703-9.
  • Yu IH, Wang Y. Fluvastatin prevents renal injury and expression of lactin like oxidized low density lipoprotein receptor-1 in rabbits white hypercholesterolemia. Chin Med J (eng). 2005;118:621-6.
  • Casey RG, Joyce M, Roche-Nagle G, Chen G, Bouchier-Hayes D. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res. 2005;132:176-81.
Data source: Dialnet